Changeflow GovPing Pharma & Drug Safety Epoxytiglienone Compounds for Disrupting Gram-n...
Routine Rule Added Draft

Epoxytiglienone Compounds for Disrupting Gram-negative Bacterial Biofilms

Favicon for changeflow.com USPTO Patent Applications - Therapeutics (A61P)
Published
Detected
Email

Summary

The USPTO has published patent application US20260097011A1 for epoxytiglienone compounds designed to disrupt biofilms comprising Gram-negative bacteria. The application covers methods of dispersing established biofilms through localized administration, including topical or injection delivery, as well as methods for preventing biofilm formation on medical devices. Inventors include David William Thomas, Paul Warren Reddell, Glen Mathew Boyle, and others. The application was filed on December 2, 2025.

What changed

The USPTO published patent application US20260097011A1 disclosing epoxytiglienone compounds and their use in disrupting Gram-negative bacterial biofilms. The application claims methods of dispersing established biofilms through exposure to epoxytiglienone compounds or salts thereof, methods of treating infections via localized administration (topical or injection), and methods of preventing biofilm formation or dispersing biofilms on medical devices.

For pharmaceutical and medical device companies, this patent application represents potential prior art that could affect freedom-to-operate analyses for anti-biofilm technologies targeting Gram-negative bacteria. Healthcare providers treating biofilm-related infections may benefit from understanding this emerging therapeutic approach. The application's broad claim scope covering both treatment methods and medical device applications suggests a wide potential utility across multiple product categories.

What to do next

  1. Monitor patent prosecution status for potential licensing opportunities
  2. Review claims for freedom-to-operate analysis in anti-infective development

Archived snapshot

Apr 13, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

BIOFILM DISRUPTION

Application US20260097011A1 Kind: A1 Apr 09, 2026

Inventors

David William THOMAS, Paul Warren REDDELL, Glen Mathew BOYLE, Jason Kingsley CULLEN, Victoria Anne GORDON, Katja Etel HILL, Lydia Charlotte POWELL, Manon F. PRITCHARD, Peter G. PARSONS

Abstract

The present invention relates to methods of dispersing biofilms comprising Gram-negative bacteria, the methods comprising exposing the biofilm to an epoxytiglienone compound or a salt thereof. Methods of treating infections comprising the localised administration, for example, topically or by injection, of an epoxytiglienone compound into or onto an established biofilm comprising Gram-negative bacteria to disrupt the structure of that biofilm and methods of preventing biofilms comprising Gram-negative bacteria forming or dispersing biofilms comprising Gram-negative biofilms that have formed on medical devices are also described.

CPC Classifications

A61K 31/336 A61K 45/06 A61P 31/04

Filing Date

2025-12-02

Application No.

19406565

View original document →

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Rule
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260097011A1

Who this affects

Applies to
Pharmaceutical companies Medical device makers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Pharmaceutical R&D Anti-biofilm therapeutics Medical device coatings
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Topics
Medical Devices Healthcare Anti-Money Laundering

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!